JPMorgan Says Buy the Dip in These 2 Large-Cap Biotech Stocks
View original at finance.yahoo.comJPMorgan Says Buy the Dip in These 2 Large-Cap Biotech Stocks Large-cap biotech stocks may be entering a very different phase from the one investors have dealt with during the past several years…
What we drew from this source
The claims Via News extracted from this document. We point to the source; we don't replace it.
Investors should be buying Alnylam Pharmaceuticals on the dip
60% confidenceSeveral important trends are developing simultaneously within large-cap biotech, including improving profitability, broader commercial diversification, a steady flow of clinical catalysts, and continued business development opportunities
60% confidenceThe biotech sector could see additional dealmaking activity in the coming quarters, creating a favorable backdrop for large-cap biotech stocks
60% confidenceMultiple biotech companies have either recently transitioned to sustained profitability or are approaching that milestone in the near term, with room for margins to expand further
60% confidenceAlnylam Pharmaceuticals has secured a Strong Buy consensus rating from the broader analyst community
60% confidenceThe large-cap biotech group is broadly at an inflection point, with a growing number of companies converting pipeline success into durable, profitable commercial franchises
60% confidence